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RESEARCH ARTICLE
New arylsparteine derivatives as positive inotropic drugs
Vito Boidoa, Marcella Ercolia, Michele Tonellia, Federica Novellia, Bruno Tassoa, Fabio Sparatorea, Elena Cicheroa,
Paola Fossaa, Paola Dorigob and Guglielmina Froldib
aDepartment of Pharmacy, University of Genoa, Genoa, Italy; bDepartment of Pharmaceutical and Pharmacological Sciences, University of
Padova, Padova, Italy
ABSTRACT
Positive inotropic agents are fundamental in the treatment of heart failure; however, their arrhythmogenic
liability and the increased myocardial oxygen demand strongly limit their therapeutic utility. Pursuing
our study on cardiovascular activities of lupin alkaloid derivatives, several 2-(4-substituted-phenyl)-2-dehy-
drosparteines and 2-(4-substituted-phenyl)sparteines were prepared and tested for inotropic and chrono-
tropic activities on isolated guinea pig atria. Four compounds (6b, 6e, 7b, and 7f) exhibited significant
inotropism that, at the higher concentrations, was followed by negative inotropism or toxicity. Compound
7e (2-(4-tolyl)sparteine) exhibited a steep dose-depending inotropic activity up to the highest concentra-
tion tested (300mM) with an Emax of 116.5 ± 3.4% of basal force, proving less potent but much more active
in comparison to the highest concentrations tested of digoxin and milrinone having Emax of 87.5 ± 3.1%
and 52.2 ± 1.1%, respectively. Finally, docking studies suggested that the relevant sparteine derivatives
could target the sigma-1 receptor, whose involvement in cardiac activity is well documented.
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Congestive heart failure (CHF) is a chronic and progressive dis-
order of left ventricular myocardial remodeling, which may lead to
acute decompensation, resulting in a major cause of death in
patients with heart disease1. To relieve symptoms and to improve
cardiac function, several classes of drugs are available, such as diu-
retics, ACE inhibitors, angiotensin receptor blockers, b-adrenergic
receptor antagonists, and others. To increase the impaired con-
tractile ability of heart, digitalis glycosides (digoxin and others) are
used since long time, while b-adrenergic agonists (ibopamine and
dobutamine) and phosphodiesterase III inhibitors (inamrinone,
milrinone, enoximone, and others) have been found to be more
profitable than digoxin in some clinical circumstances2–4.
Unfortunately, these drugs are not tolerated for long-term therapy
and may even exacerbate the myocardial abnormality with disap-
pointing effect on mortality rate.
Thus, despite the narrow therapeutic index, digoxin has been
re-appraised, but better tolerated inotropics, possibly acting
through novel mechanisms, with reduced myocardial oxygen
demand and lower arrhythmogenic liability are actively pursued.
Indeed, in the last years, novel chemotypes and biological targets
have been investigated producing a number of promising com-
pounds, such as istaroxime, ivabradine, levosimendan, and ome-
camtiv mecarbil, which are described in several reviews5–10.
Some other compounds, among those displaying positive ino-
tropic activity, appear to have been somewhat underestimated. In
fact, even possessing only moderate inotropic activity, they target
different heart structures with antiarrhythmic and/or coronaro-
dilator effects. Particularly, we deemed of interest the family of
lupin (quinolizidine) alkaloids, whose pharmacophoric template
has been only limitedly explored for drug development.
Positive inotropic activity, besides antiarrhythmic action, was
observed for ()-sparteine (1), (±)-lupanine (2) (Figure 1), and
other structurally related alkaloids11a–11d in isolated atria of rat or
guinea pig; however, the positive inotropic action was not con-
firmed in the intact heart of anesthetized dog11c,12. Particularly,
Philipsborn et al.11b reported for sparteine sulfate, in the range
from 1.6mM to 1.6mM concentration, a gradual increase of the
inotropic activity in electrically driven guinea pig left atria, with a
maximum increase of 22% of contractile force at 100 mM concen-
tration; no variation was observed up to 100mM concentration, in
the case of spontaneously beating right atria. Beyond 100 mM con-
centration, a steep decrease of activity was observed in both kinds
of atria preparations, reaching 70% at the highest tested
concentration.
Direct positive inotropic action on isolated cardiac muscle of
guinea pig and bullfrog was described for another kind of tetra-
cyclic lupin alkaloids, as (þ)-matrine (3) and ()-sophoramine (4)13
(Figure 1).
In order to improve the cardiovascular activity of sparteine,
some modifications of its structure have been also explored. A set
of 17-alkylsparteines (from 17-methyl to 17-hexylsparteine) (5,
R¼ alkyl) showed improved inotropic effects in electrically stimu-
lated guinea pig atria11d,14. According to Engelmann et al.11d, in
electrically driven guinea pig atria, sparteine produced a maximal
increase (þ42%) of contractile force at 200mM concentration,
while the 17-ethylsparteine, at the same concentration,
displayed a þ60% increase that reachedþ81% at the highest
tested concentration (800 mM), resulting the most active 17-
alkylsparteine derivative as inotropic. On the contrary, 17-butyl
and 17-pentylsparteines were the best as antifibrillatory agents14.
The replacement of the 17-alkyl substituents with heteroaryl-,
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heteroarylalkyl- and benzyl-moieties led to compounds with
antiarrhythmic activity and reduced oxygen consumption by myo-
cardium, so that 17-(3-methoxybenzyl)sparteine (5, R¼ 3-methoxy-
benzyl) was suggested for the therapy of coronary
insufficiency15a,15b (Figure 1).
Some 2-alkyl- and 2-arylderivatives of 2-dehydrosparteine (6,
R¼H, OCH3) and sparteine (7, R¼H, OCH3) were recognized to
display 10- to 30-fold higher antifibrillatory activity on isolated
frog heart in comparison to sparteine16,17, but the eventual ino-
tropic activity was not investigated (Figure 1).
Finally, through a pharmacological screening of assorted quino-
lizidine derivatives performed, some years ago, by “Panlabs Inc.”
(Bothell, WA), we observed that the 2-(4-fuorophenyl)sparteine dis-
played a significant positive inotropic activity on electrically driven
guinea pig atria. Therefore, pursuing our long standing study
about cardiovascular activity of derivatives of lupin alkaloids18–22,
we deemed interesting to extend the study of inotropic activity
to twelve 2-aryl-2-dehydrosparteine and 2-arylsparteine of struc-
tures 6 and 7, respectively, with R¼H, F, Cl, OCH3, CH3, and CF3
(Figure 2), thus including the four compounds previously investi-
gated by Winterfeld et al.16,17 for the antifibrillatory activity.
Materials and methods
General
Chemicals, solvents, and reagents used for the syntheses were
purchased from Sigma-Aldrich (St. Louis, MO), Fluka (Newport
News, VA), or Alfa Aesar (Ward Hill, MA), and were used without
any further purification. Column chromatography (CC): silica gel
(Merck, Darmstadt, Germany). Mps: B€uchi apparatus (B€uchi, Flawil,
Switzerland), uncorrected. 1H NMR and 13C NMR spectra: Varian
Gemini-200 spectrometer (Varian Medical Systems (VAR), Palo Alto,
CA); CDCl3; d in ppm rel. to Me4Si as an internal standard; J in Hz.
Elemental analyses were performed on a Carlo Erba EA-1110
CHNS-O instrument in the Microanalysis Laboratory of the
Department of Pharmacy of Genoa University.
Extraction of (±)-lupanine
The ground seeds of Lupinus albus L. (1 kg) were extracted with
light petroleum ether in a Soxhlet apparatus for 24 h to eliminate
the lipidic materials. Successively the air dried material was further
extracted with methanol for about 36 h. The methanol solution was
filtered and concentrated to small volume in a B€uchi Rotavapor
(B€uchi, Flawil, Switzerland). To the concentrated extract, 300mL of
water followed by 150mL of 2 N hydrochloric acid were added and
the acidic solution was filtered and extracted three times with ether
to eliminate all non-basic compounds. The acidic solution was basi-
fied with 6 N sodium hydroxide solution and extracted with chloro-
form (5 100mL). After drying (Na2SO4), the chloroform was
evaporated in Rotavapor obtaining 22.7 g of an oil that partially
crystallized standing in cold. The addition of a little of acetone
allowed the filtration of the crystals that were recrystallized from
acetone yielding 8.3 g of pure (±)-lupanine melting at 95–97 C.
The joined acetone solution was evaporated to dryness and
the residue was chromatographed on basic alumina (220 g) eluting
with chloroform (15 40mL). The elimination of the solvent left
6.65 g of crystals that were rinsed with a little of acetone yielding
5.5 g of (±)-lupanine with m.p. 93–94 C. Therefore, the total yield of
(±)-lupanine was 1.38% in respect to the seeds used.
2-(4-Substituted-phenyl)-2-dehydrosparteines (6). (General method)
A solution of aryl magnesium bromide (20.1mmol) was prepared
by reacting at r.t. Mg turnings (0.51 g, 21.0mmol) in dry Et2O
(10mL), activated by methyl iodide and iodine, with a solution of
the proper aryl bromide (20.1mmol) in dry Et2O (10mL). Then a
solution of lupanine (2 g, 8.1mmol) in dry Et2O (50mL) was added.
After being refluxed for 2 h, to the cooled (0–5 C) reaction mix-
ture, 50mL of a solution of 2N HCl were added, then the resulting
mixture was washed with Et2O in order to remove the aromatic
compounds derived from the exceeding arylmagnesium bromides.
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Figure 1. Lupin alkaloids and derivatives investigated as inotropic agents.
Figure 2. Inotropic effects of digoxin, milrinone and compound 7e. p< 0.05
compound 7e versus milrinone.
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extracted with Et2O. The dried organic layer (Na2SO4) was evapo-
rated, leaving an oily residue that was purified by CC(SiO2/
Et2Oþ 2%DEA) and, when necessary, crystallized from the proper
solvent.
2-Phenyl-2-dehydrosparteine (6a) Yield: 35%. Mp 99–100 C (acet-
one) [lit. (16a): 103–105 C]. 1H NMR (200MHz, CDCl3): 1.10–2.48
(m, 18H), 2.70–3.04 (m, 4 H), 4.41–4.53 (m, 1H, C(3)), 7.18–7.43 (m,
5H, ArH). Anal. Calcd for C21H28N2þ0.25H2O: C, 80.59; H, 9.18; N,
8.95. Found: C, 80.71; H, 9.14; N, 8.77.
2-(4’-Fluorophenyl)-2-dehydrosparteine (6b) Yield: 49%. Mp
124–125 C (Et2O).
1H NMR (200MHz, CDCl3): 1.10–2.47 (m, 18H),
2.70–2.95 (m, 4 H), 4.44–4.56 (m, 1H, C(3)), 6.92–7.07 (m, 2 H, ArH),
7.21–7.37 (m, 2H, ArH). 13C NMR (50MHz, CDCl3): 163.18, 158.31,
146.90, 135.27, 128.38, 101.33, 63.39, 61.27, 54.68, 53.66, 51.81,
35.06, 33.34, 31.89, 26.67, 25.81, 24.76, 23.96, 21.70. Anal. Calcd for
C21H27FN2: C, 77.26; H, 8.34; N, 8.58. Found: C, 77.21; H, 8.35;
N, 8.49.
2-(4’-Chlorophenyl)-2-dehydrosparteine (6c) Yield: 37%. Mp
130–133 C (Et2O).
1H NMR (200MHz, CDCl3): 1.09–2.40 (m, 18H),
2.68–2.94 (m, 4 H), 4.46–4.57 (m, 1H, C(3)), 7.27 (pseudo s, 4 H,
ArH). 13C NMR (50MHz, CDCl3): 146.84, 137.75, 131.41, 128.10,
127.06, 101.77, 63.38, 61.27, 54.67, 53.71, 51.77, 35.03, 33.34, 31.87,
26.66, 25.74, 24.75, 23.95, 21.72. Anal. Calcd for C21H27ClN2: C,
73.56; H, 7.92; N, 8.17. Found: C, 73.22; H, 8.01; N, 8.11.
2-(4’-Methoxyphenyl)-2-dehydrosparteine (6d) Yield: 38%. Oil (lit.
(16b): oil, b.p. 194–202 C, high vacuum). 1H NMR (200MHz,
CDCl3): 1.00–3.35 (m, 22H), 3.88 (s, OCH3), 4.45–4.67 (m, 1H, C(3)),
6.92 (d, J¼ 10.0 Hz, 2 H, ArH), 7.36 (d, J¼ 10.0 Hz, 2 H, ArH).
Elemental analysis produced results not well fitting for the formula
C22H30N2O, due to the instability of the compound.
2-(4’-Tolyl)-2-dehydrosparteine (6e) Yield: 39%. Mp 102–103 C
(acetone) [(lit.23: 113–115 C]. 1H NMR (200MHz, CDCl3): 1.09–2.44
(m, 18H and 2.34, s, CH3, superimposed), 2.68–3.03 (m, 4 H),
4.46–4.56 (m, 1H, C(3)), 7.12 (d, J¼ 9.8 Hz, 2 H, ArH), 7.23 (d,
J¼ 9.8 Hz, 2 H, ArH). 13C NMR (50MHz, CDCl3): 147.85, 136.40,
135.36, 127.56, 126.73, 100.68, 63.28, 61.27, 54.68, 51.85, 35.09,
33.40, 31.98, 26.73, 25.88, 24.84, 23.97, 21.76, 20.10. Anal. Calcd
for C22H30N2: C, 81.94; H, 9.38; N, 8.69. Found: C, 82.15; H, 9.45;
N, 8.70.
2-(4’-Trifluoromethyl)-2-dehydrosparteine (6f) Yield: 28%. Mp
98–99 C (acetone). 1H NMR (200MHz, CDCl3): 1.05–2.47 (m, 18H),
2.69–3.03 (m, 4 H), 4.46–4.54 (m, 1H, C(3)), 7.44 (d, J¼ 9.2 Hz, 2 H,
ArH), 7.58 (d, J¼ 9.0 Hz, 2 H, ArH). 13C NMR (50MHz, CDCl3):
146.87, 142.96, 127.56, 126.98, 123.87, 102.98, 63.46, 61.27, 54.70,
53.78, 51.73, 34.99, 33.23, 31.83, 26.61, 25.67, 24.67, 23.92, 21.77.
Anal. Calcd for C22H27F3N2: C, 70.19; H, 7.22; N, 7.44. Found: C,
70.00; H, 7.19; N, 7.40.
2-(4-Substituted-phenyl)sparteines (7). (General method)
A solution of the suitable 2-dehydrosparteine derivative (1.6mmol)
in 20mL of EtOH was hydrogenated at r.t. and atmospheric pres-
sure in the presence of 10% Pd/C (0.1 g). After about 1 h, the cal-
culated volume of H2 was absorbed. The catalyst was removed
and the solvent was evaporated in vacuo, affording a residue that
was crystallized from the indicated solvent.
2-Phenylsparteine (7a) Yield: 62%. Mp 91–92 C (Et2O) [lit.
16a: oil,
b.p. 160–161 C, high vacuum]. 1H NMR (200MHz, CDCl3):
1.04–2.18 (m, 20H), 2.37–3.08 (m, 5H), 7.19–7.55 (m, 5H, ArH).
Anal. Calcd for C21H30N2: C, 81.24; H, 9.74; N, 9.02. Found: C, 81.39;
H, 9.84; N, 9.08.
2-(4’-Fluorophenyl)sparteine (7b) Yield: 70%. Mp 101–102 C
(Et2O).
1H NMR (200MHz, CDCl3): 1.02–2.16 (m, 21H), 2.22–3.05 (m,
4 H), 6.90–7.12 (m, 2H, ArH), 7.23–7.48 (m, 2H, ArH). 13C NMR
(50MHz, CDCl3): 162.96, 158.11, 140.63, 127.74, 67.46, 65.28, 63.53,
57.44, 54.70, 52.69, 36.08, 35.11, 33.48, 32.76, 28.85, 26.80, 24.87,
23.90, 23.48. Anal. Calcd for C21H29FN2: C, 76.90; H, 8.90; N, 8.53.
Found: C, 76.79; H, 8.97; N, 8.50.
2-(4’-Methoxyphenyl)sparteine (7d) Yield: 72%. Oil. [lit.16b: oil, b.p.
188 C, high vacuum]. 1H NMR (200MHz, CDCl3): 1.03–2.10 (m,
20H), 2.35–2.57 (m, 2H), 2.69–2.93 (m, 3H), 3.82 (s, OCH3), 6.85 (d,
J¼ 10.0 Hz, 2 H, ArH), 7.24 (d, J¼ 10.0 Hz, 2 H, ArH). Anal. Calcd for
C22H32N2O: C, 77.60; H, 9.47; N, 8.23. Found: C, 77.28; H, 9.45; N,
8.07. Dihydrochloride Mp 245–246 C. Anal. Calcd for
C22H34Cl2N2OþH2O: C, 61.24; H, 8.41; N, 6.49. Found: C, 61.68; H,
8.43; N, 6.16.
2-(4’-Tolyl)sparteine (7e) Yield: 40%. Mp 80–82 C (Et2O) [lit.
24:
81–83 C]. 1H NMR (200MHz, CDCl3): 1.04–2.18 (m, 20H), 2.25–2.60
(m, 2H and 2.33, s, CH3, superimposed), 2.70–2.96 (m, 3 H), 7.12 (d,
J¼ 10.0 Hz, 2 H, ArH), 7.23 (d, J¼ 10.0 Hz, 2 H, ArH). 13C NMR
(50MHz, CDCl3): 142.02, 134.98, 127.96, 126.28, 68.00, 65.34, 63.46,
57.50, 54.70, 52.73, 36.08, 35.15, 33.50, 32.83, 28.94, 26.86, 24.91,
23.90, 23.62, 20.07. Anal. Calcd for C22H32N2: C, 81.43; H, 9.94; N,
8.63. Found: C, 81.47; H, 10.05; N, 8.67.
2-(4’-Trifluoromethyl)sparteine (7f) Yield: 48%. Mp 68–70 C (acet-
one). 1H NMR (200MHz, CDCl3): 1.03–2.14 (m, 20H), 2.30–2.57 (m,
2H), 2.70–3.07 (m, 3H), 7.43 (d, J¼ 10.0 Hz, 2 H, ArH), 7.66 (d,
J¼ 10.0 Hz, 2 H, ArH). 13C NMR (50MHz, CDCl3): 146.90, 142.97,
127.52, 126.61, 123.89, 67.95, 65.13, 63.61, 57.62, 54.69, 52.55,
35.92, 35.04, 33.33, 32.66, 28.75, 26.65, 24.76, 23.80, 23.40. Calcd
for C22H29F3N2: C, 69.82; H, 7.72; N, 7.40. Found: C, 69.62; H, 7.80;
N, 7.32.
2-(4’-Chlorophenyl)sparteine (7c) A solution of 2-(4’-chlorophenyl)-
2-dehydrosparteine (0.73mmol, 0.25 g, 6c) in 4mL of EtOH was
added with NaBH4 (3.3mmol, 125mg) and refluxed for 4 h with
stirring. After removing the solvent, the residue was treated drop-
wise, and in the order, with 3mL of H2O, 3mL of 2N NaOH and
extracted with Et2O. The organic layer was dried (Na2SO4), filtered,
and concentrated to dryness, affording the title compound.
Yield: 95%. Mp 75–77 C (Et2O).
1H NMR (200MHz, CDCl3):
1.00–3.10 (m, 23H), 3.38–3.57 (m, 2H), 7.15–7.38 (m, 4H, ArH). 13C
NMR (50MHz, CDCl3): 143.53, 130.92, 127.71, 127.43, 67.57, 65.21,
63.54, 57.53, 54.70, 52.68, 35.96, 35.10, 33.48, 32.74, 28.81, 26.79,
24.86, 23.88, 23.45. Anal. Calcd for C21H29ClN2: C, 73.12; H, 8.47; N,
8.12. Found: C, 72.55; H, 8.49; N, 7.93.
Docking studies
All the compounds were built, parameterized (Gasteiger–Huckel
method) and energy minimized within MOE using MMFF94 force-
field25. For the newly synthesized sparteine derivative 7b–f
the two R and S enantiomers were taken into account and built
in silico.
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Docking calculations within the X-ray structure of human
sigma-1 receptor (pdb code¼ 5HK1) were performed using the
MOE-DOCK tool, implemented in MOE. The compound best-
docked pose, evaluated in terms of “London dG”, was refined by
energy minimization (MMFF94) and rescored according to “Affinity
dG” (kcal/mol of total estimated binding energy). The final score
(based on the latest refinement step which has been applied)
namely S score, was considered to prioritize any ligand
conformation.
In addition, the best docking geometry was refined by ligand/
protein complex energy minimization (CHARMM27) and success-
fully assessed using a short 1 ps run of molecular dynamics (MD)
at constant temperature, followed by an all-atom energy minimiza-
tion (LowModeMD implemented in MOE software). This kind of
module was allowed to perform an exhaustive conformational
analysis of the ligand–receptor binding site complex, as we
already discussed about other case studies, where it proved to be
useful for a preliminary evaluation of docking poses26.
Pharmacological studies
Animals
Dunkin–Hurtley male guinea pigs (300–500 g), obtained from
Harlan Italy (S. Pietro al Natisone, Italy), were kept in controlled
environmental conditions (temperature: 23 ± 2 C; light–dark cycle:
7 a.m. to 7 p.m.). Animals had free access to a standard laboratory
diet and to water. All animal-use procedures described in this
paper were in accordance with the National Institutes of Health
guidelines for the Care and Use of Laboratory Animals and comply
with the ethical principles and guidelines adopted by the
European Community, law 86/609/CEE. The experimental protocol
was approved by the local veterinary committee.
In order to obtain myocardial tissues depleted in endogenous
catecholamines, the animals were treated daily for 2 d with reser-
pine (2mg/kg i.p.) and anesthetized with methoxyflurane before
sacrifice.
Assessment of inotropic and chronotropic activities on isolated
atrial preparations
The atria were separated from ventricles and suspended vertically
in a 30mL organ bath containing a physiological salt solution con-
stantly gassed by 95% O2 and 5% CO2, at 30 C. The bathing solu-
tion contained (mM): NaCl 120, KCl 2.7, CaCl2 1.36, MgCl2 0.09,
NaH2PO4 0.4, NaHCO3 12 and glucose 5.5 (pH¼ 7.5). The resting
tension was adjusted at 10.0mN and the developed tension was
recorded isometrically by means of a high-sensitivity transducer
(Ugo Basile, type DYO Comerio, Italy) connected to a PC-based
Acqknowledge acquisition system (BIOPAC Systems, Inc., 42 Aero
Camino Santa Barbara, CA). The drugs were added to the perfu-
sion fluid after 90min of equilibration. Since the atria were iso-
lated from reserpine treated animals, before the beginning of
experiments, the depletion of catecholamines was verified by lack
of any positive inotropic effect induced by tyramine (2mg/mL).
Experiments were performed only in preparations that did not
respond to tyramine. Test compounds and milrinone were added
cumulatively and the effects caused by each drug concentration
were recorded up to the maximum response before a higher con-
centration was added. The effects of each compound on the force
of contraction and the frequency were expressed as the percent
increase/decrease over controls (D%). Compounds were dissolved
in physiological solution or in the stoichiometric 0.5 N HCl,
while milrinone was dissolved in dimethyl sulfoxide (DMSO).
The final concentration of DMSO in the medium did not influence
the basal activity of the atrial preparations. The statistical compari-
sons between treatment and control data were performed by
ANOVA followed by Bonferroni t test; a value of p< 0.05 was con-
sidered statistically significant.
General pharmacological screening
For in vivo tests, compounds were generally administered orally
(p.o) by gavage; they were prepared as aqueous solutions or finely
homogenized suspensions in "tween 80" (2%). In a few cases, the
substances were introduced intraperitoneally (i.p.). Groups of three
or five animals (mice or rats) were used. For in vitro assays, some-
times it was necessary to increase the solubility by means of
DMSO in a concentration not interfering with the tests (0.1% for
platelet aggregation and 0.5% for all the others).
Doses (mg/kg) or concentrations (mg/mL) indicated in the fol-
lowing methods were the highest commonly utilized; when signifi-
cant activity was detected, lower doses or concentrations were
tested in order to define the minimal effective ones.
Maximal tolerated dose, autonomic signs, and Irwin test
Three mice were dosed at 300mg/kg p.o. and 100mg/kg i.p. for
observation of acute toxic symptoms or autonomic effects during
the subsequent 72 h. If none was noted, pharmacological evalu-
ation proceeded employing doses and concentrations for each
test based on appropriate multiple of doses required by suitable
reference compounds. If acute toxicity was observed initially, the
maximal tolerated dose was determined and pharmacological
screening doses were reduced proportionally.
Before and 1 h after dosing mice with test samples, 10 parame-
ters indicating motor stimulation (irritability, hyperactivity,
increased palpebral size, increased startle response, increased
response to touch, increased exploration, piloerection, strand tail,
tremors, convulsions) were measured. Normalcy for each is 0; max-
imum abnormal condition for each score 2 10 3 mice¼ 60.
Scores greater than 12 denote significant stimulation. Similarly, 10
parameters (pinna reflex, spontaneous activity, palpebral size, star-
tle response, touch response, reactivity, placing, righting reflex,
exploration, and ataxia) were measured for behavioral depression.
Each parameter scores 2 points for normalcy for a total of
2 10 3¼ 60 points possible. Scores below 40 denote significant
behavioral depression.
Blood pressure
Two spontaneously hypertensive rats (SHR) with systolic blood
pressures ranging between 180 and 220mmHg were used.
Blood pressure was determined by tail-cuff method in a tem-
perature-controlled environment (32 ± 1 C) before, 1, 2, and 4 h
after test substance administration p.o. (100mg/kg). Reduction in
systolic blood pressure by more than 10% at any two of the
aforementioned three consecutive time intervals is considered
significant.
Heart rate
The same SHRs employed in the preceding test were used.
Heart rate was recorded by ECG, immediately after blood
pressure recordings, before and 1, 2, and 4 h post-treatment p.o.
(100mg/kg). An increase or a decrease in heart rate greater than
20% from pretreatment control readings indicates significant
tachycardia or bradycardia, respectively.
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Antiarrhythmic activity
The substance was administered i.p. (30mg/kg) to a group of 3
mice 30min before exposure to deep chloroform anesthesia and
observed during the following 15min period. The absence of ECG
recorded cardiac arrhythmias and heart rate above 200 beats/min
(usually 400–480 beats/min) in at least two mice indicates signifi-
cant protection.
In vitro inotropic effect
Test substance (10 mg/mL)-induced variation in contractile force of
electrically stimulated (95% of maximum, 150 beats/min) guinea
pig left atria, bathed in physiological salt solution containing one
third normal calcium concentration at 32 C, by more than 40%
indicates significant (±) inotropic activity. Only inamrinone sensi-
tive preparations were used.
In vitro chronotropic effect
Test substance (10 mg/mL)-induced change in atrial rate in spon-
taneously beating guinea pig atria, bathed in physiological salt
solution at 37 C, by more than 10% is considered significant.
Effects on diuresis, saluresis, and kaluresis
Groups of three overnight-fasted rats were used. Each group was
hydrated with distilled water (25mL/kg, p.o.) administered
together with test substance (30mg/kg, p.o.) or vehicle. Urine
volume was measured over the ensuing 6 h period and analyzed
for Naþ and Kþ contents, expressed as meq/100 g body weight.
A greater than 50% increase or decrease in urine volume in test
versus control animals was considered a significant effect. A
greater than two-fold increase of Naþ and Kþexcretion in test
versus control animals was considered a significant saluretic or
kaluretic effect.
In vitro tracheal relaxation
The strip preparations of isolated guinea pig trachea was used to
study the contractile tension, placed in physiological salt solution
at 37 C under 4.9mN. Test substance (100mg/mL) inhibition of
tracheal tone by more than 50%, relative maximal relaxation
induced by 0.3mg/mL epinephrine, indicates significant activity. If
test substance-induced relaxation is antagonized more than 50%
by propranolol (2 mg/mL), a well known b2-adrenoceptor blocker,
an agonist action is indicated.
Anti-inflammatory activity
In a group of three overnight-fasted rats, test substance was
administered p.o. (100mg/kg) 1 h before right hind paw intra-plan-
tar injection of carrageenan (0.1mL, 1% suspension). Inhibition of
paw edema by more than 30% 3h after carrageenan administra-
tion indicates acute anti-inflammatory activity.
Analgesic activity
Writhing test: Test sample was administered p.o. (100mg/kg) to a
group of 3 mice 1 h before injection of phenylquinone (2mg/kg,
i.p.), greater than 50% inhibition of the number of twists per
group of animals observed during 5–10min after phenylquinone,
relative to a vehicle-treated group, indicates possible analgesic
activity.
Formalin test: Test sample was administered p.o. (30mg/kg) to
a group of 5 mice 1 h before sub-plantar injection of formalin
(0.02mL, 1% sol.) into the right hind paw. Reduction of the
induced paw licking time recorded during the following 20–30min
period by more than 50% indicates analgesic activity.
In vitro platelet aggregation inhibition
Sodium arachidonate induced aggregation: Test substance
(10 mg/mL) inhibition by more than 50% of maximum non-
reversible platelet aggregation (rabbit platelet-rich plasma, RPP)
induced by sodium arachidonate (50 mg/mL) indicates significant
activity.
ADP induced aggregation: Test substance (100mg/mL) inhibition
by more than 50% of maximum non-reversible platelet aggrega-
tion (RPP) induced by adenosine diphosphate (ADP, 0.4–0.8 mg/mL)
indicates significant activity.
PAF induced aggregation: Test substance (10 mg/mL) inhibition
by more than 50% of maximum non-reversible platelet aggrega-
tion (RPP) induced by platelet activating factor (PAF-acether,
10–20 ng/mL) indicates significant activity.
Results and discussion
Synthesis
The required compounds were prepared by reacting (±)-lupanine
(extracted from seeds of Lupinus albus) with the proper 4-substi-
tuted phenylmagnesium bromides.
The initially formed carbinolamines could not be isolated even
in the mildest working up procedures. The reduction of 2-dehy-
drosparteine derivatives (6) was commonly performed by catalytic
hydrogenation (Pd/C), or by the action of sodium borohydride in
the case of compound 6c, in order to avoid the chlorine hydroge-
nolysis. The methoxy derivative 6d was rather unstable and was
immediately converted into the saturated compound 7d.
Biological results
Pharmacology: general considerations
Ten compounds (6b, 6c, 6e, 6f, and 7a–f) were tested in vitro for
inotropic and chronotropic activities on spontaneously beating
atria obtained from guinea pigs pretreated with reserpine in order
to avoid the influence of endogenous catecholamines released
from nerve terminals (Tables 1 and 2). Two compounds could not


























R= H (a); F (b); Cl (c); OCH3 (d); CH3 (e); CF3 (f)
a)
b) c) or d)
Scheme 1: Reagents and conditions: (a) dry Et2O; reflux, 2 h; (b) dil. HCl; (c)
H2/Pd-C, EtOH, r.t.; (d) NaBH4, EtOH; reflux, 4 h. (±)-lupanine, for the sake of sim-
plicity, only one enantiomer is shown.
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Moreover, the so far unpublished results of the previous
pharmacological screening of compound 7b, in comparison with
milrinone, were included, providing some additional information
on other cardiovascular and related activities and on toxicity of
this kind of compounds (Table 3).
Inotropic and chronotropic activities
As it is illustrated in Table 1, the dehydrosparteine derivatives 6b
and 6e showed a concentration-dependent positive inotropic
effect that at the higher concentrations of 100 and 300 mM was
converted to negative inotropism. A similar positive inotropism
was observed for compounds 7b and 7f which, however, at 100
and 300 mM induced overt toxicity characterized by the appear-
ance of arrhythmias and functional derangement leading to the
irreversible stop of atrial contractions. It is worth noting that, at
the highest non-toxic concentration (30mM), compound 7b dis-
played an inotropic effect (þ30%) comparable with that previously
observed on electrically driven atria of non-reserpinized guinea
pig (þ56%, see Table 3).
At concentrations up to 30 mM, compounds 6b, 6e, and 7b
exhibited only modest (<6%) positive or negative chronotropic
activities (Table 2), while compound 7f exhibited moderate posi-
tive chronotropism (up toþ19%). At higher concentrations, all the
cited compounds showed either negative chronotropism or tox-
icity (Table 2).
Very interestingly, the 2-(4-tolyl)sparteine 7e exhibited a steep
enhancement of contractile strength up to the maximal concentra-
tion tested (300 mM), with an Emax of 116.5 ± 3.4% of the basal con-
tractile force. This powerful positive inotropism was associated
with only a moderate increase of the beating rate that reach-
edþ27.3 ± 0.3% at the highest concentration (300mM).
The remaining compounds, including 2-phenylsparteine 7a and
2-(4-methoxyphenyl)sparteine 7d (tested in the past16,17 for antifi-
brillatory activity), were endowed with modest positive inotropism
at the lower concentrations, followed by increasing negative ino-
tropism or toxicity at the higher concentrations. Similar effects
were observed concerning the beating frequency.
Further, the inotropic activity of 7e was compared with that of
two well-known inotropic drugs digoxin and milrinone. Figure 2
reports the concentration–effect curves of the three inotropic
agents showing that digoxin was the most potent, increasing the
basal contractile force by 50% at 0.9mM concentration, while com-
pound 7e was the most efficacious with an Emax¼ 116% at 300 mM
concentration. Milrinone was moderately potent but the least
active. Concentrations of digoxin higher than 3 mM could not be
tested because of toxicity.
Table 2. Effect of compounds 6b, c, e, f, 7a–f, and milrinone (M) on the frequency rate (chronotropism) of isolated atria of guinea pigs pretreated with reserpine.
Frequency (D%)
Comp. R 107 M 3 107 M 106 M 3 106 M 105 M 3 105 M 104 M 3 104 M
6ba F 1.33 ± 0.19 1.77 ± 0.18 3.35 ± 0.21 1.56 ± 0.18 0.73 ± 0.09 0.55 ± 0.04 2.50 ± 0.18 5.00 ± 0.22
6ca Cl 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 4.00 ± 0.12 28.00 ± 0.12 32.00 ± 0.43 tox tox
6ea CH3 1.59 ± 0.23 3.09 ± 0.25 5.79 ± 0.31 5.97 ± 0.32 3.11 ± 0.27 2.02 ± 0.24 7.25 ± 0.26 12.05 ± 0.29
6fa CF3 0.45 ± 0.20 0.77 ± 0.21 1.94 ± 0.15 3.83 ± 0.18 7.74 ± 0.64 17.96 ± 0.22 20.83 ± 0.84 40.97 ± 0.71
7ab H 0.45 ± 0.03 0.98 ± 0.07 1.31 ± 0.09 1.50 ± 0.07 2.03 ± 0.11 4.25 ± 0.21 tox tox
7ba F 0.28 ± 0.03 0.67 ± 0.04 0.78 ± 0.05 1.33 ± 0.04 5.21 ± 0.21 4.41 ± 0.31 tox tox
7cb Cl 3.70 ± 0.19 4.35 ± 0.21 4.35 ± 0.18 4.35 ± 0.21 13.04 ± 0.31 26.08 ± 0.41 tox tox
7db OCH3 1.14 ± 0.18 2.39 ± 0.19 6.84 ± 0.30 6.99 ± 0.30 10.96 ± 0.41 5.50 ± 0.39 tox tox
7eb CH3 0.71 ± 0.03 0.92 ± 0.07 1.12 ± 0.10 2.27 ± 0.12 7.39 ± 0.20 19.33 ± 0.28 25.73 ± 0.31 27.27 ± 0.32
7fb CF3 0.58 ± 0.02 0.58 ± 0.03 5.69 ± 0.24 10.88 ± 0.48 14.39 ± 0.38 19.22 ± 0.41 tox tox
Mc nt nt 3.01 ± 0.24 9.12 ± 0.05 11.52 ± 0.33 18.22 ± 0.84 24.46 ± 0.75 32.81 ± 1.04
Test compounds were added cumulatively to the bathing fluid, and chronotropic effect was recorded for 5min after they reached maxima, before adding a higher
concentration. The value of basal heart rate was 132.0 ± 3.5 bpm. Results are means ± SEM of 6–10 experiments. Negative value indicates a negative chronotropic
effect. nt: not tested; tox: toxicity.
aDissolved in 0.5N HCl.
bDissolved in physiological solution.
cDissolved in DMSO.
Table 1. Effect of compounds 6b, c, e, f, 7a–f, and milrinone (M) on the force of contraction (inotropism) of isolated atria of guinea pigs pretreated with reserpine.
Developed tension (D%)
Comp. R¼ 107 M 3 107 M 106 M 3 106 M 105 M 3 105 M 104 M 3 104 M
6ba F 1.82 ± 0.02 3.01 ± 0.03 7.07 ± 0.04 15.88 ± 0.07 29.44 ± 0.11 32.88 ± 0.14 28.57 ± 0.12 57.14 ± 0.22
6ca Cl 3.70 ± 0.13 7.40 ± 0.11 3.70 ± 0.09 3.70 ± 0.08 14.80 ± 0.12 29.60 ± 0.14 tox tox
6ea CH3 4.10 ± 0.01 10.64 ± 0.05 19.38 ± 0.07 28.44 ± 0.12 26.99 ± 0.17 24.69 ± 0.16 29.76 ± 0.13 58.33 ± 0.24
6fa CF3 0.65 ± 0.01 0.78 ± 0.02 0.09 ± 0.01 9.02 ± 0.02 12.93 ± 0.04 33.09 ± 0.15 48.21 ± 0.57 74.10 ± 0.86
7ab H 0.00 ± 0.00 0.00 ± 0.00 1.56 ± 0.09 2.75 ± 0.10 0.72 ± 0.03 3.73 ± 0.08 tox tox
7ba F 1.50 ± 0.23 2.14 ± 0.18 5.17 ± 0.24 9.53 ± 0.24 20.85 ± 0.36 29.99 ± 0.37 tox tox
7cb Cl 0.00 ± 0.00 0.00 ± 0.00 4.17 ± 0.24 16.67 ± 0.18 29.17 ± 0.20 tox tox tox
7db OCH3 0.01 ± 0.01 0.34 ± 0.02 0.83 ± 0.03 1.65 ± 0.04 1.39 ± 0.04 5.01 ± 0.07 tox tox
7eb CH3 1.97 ± 0.15 2.55 ± 0.17 3.27 ± 0.09 9.76 ± 0.10 38.81 ± 0.35 68.96 ± 1.15 110.71 ± 2.77 116.50 ± 3.41
7fb CF3 1.64 ± 0.16 8.63 ± 0.21 17.45 ± 0.17 27.02 ± 0.21 43.08 ± 0.40 41.32 ± 0.25 tox tox
Mc nt nt 16.69 ± 0.95 30.24 ± 0.75 38.68 ± 1.25 46.16 ± 0.80 52.70 ± 0.83 52.25 ± 1.13
Test compounds were added cumulatively to the bathing fluid, and inotropic effect was recorded for 5min after they reached maxima, before adding a higher con-
centration. The value of basal force of contraction was 7.23 ± 0.32mN. Results are means ± SEM of 6–10 experiments. Negative value indicates negative inotropism
(decrease of developed tension). nt: not tested; tox: toxicity.
aDissolved in 0.5N HCl.
bDissolved in physiological solution.
cDissolved in DMSO.
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Comparing chronotropism of the three agents, it was observed
(Figure 3) that digoxin increased the frequency up to 25% on
basal value at the concentration of 3mM; furthermore, higher con-
centrations induced high toxicity with arrhythmias and atrial block.
Instead, the compound 7e slightly increased frequency, much less
than digoxin, and also less than milrinone without ever causing
severe cardiac toxicity (Figure 3).
The structural features that characterized the studied com-
pounds (the presence or the absence of the enaminic double
bond and consequent variation of the configuration of the tetra-
cyclic system; nature of the substituent on the aromatic moiety)
clearly influence both inotropic and chronotropic activities. On the
whole, the 2-dehydrosparteine derivatives were more prone to
produce negative inotropism and, even more, negative chrono-
tropism, in comparison with the saturated compounds. However,
the influence on the activity exerted by the presence of the
enaminic double bond is not constant in the four couples of com-
pounds bearing the same substituent on the aromatic moiety
(compare 6b/7b; 6c/7c; 6e/7e; 6f/7f). The influence on the activity
of the structural features is also variable in relation to the tested
concentrations, because they may exert different effects in relation
to permeability of cardiac tissue and intracellular targets respon-
sible for the force and the frequency of cardiac contraction.
Anyhow, among the 2-dehydrosparteines (6), the highest and
lowest inotropic activities were found for the fluorophenyl (6b)
and the trifluoromethylphenyl (6f) derivatives, respectively. On the
contrary, among the saturated compounds (7), the fluorophenyl
(7b) was less active than the trifluoromethylphenyl (7f) derivative
that was the most active of the whole set of compounds up to
the 10mM concentration, beyond which it was largely surmounted
by the methylphenyl analog 7e. Indeed, the concentration–effect
curve of 7f is rather flattened and parallel to that of milrinone up
Table 3. General pharmacological screening of compound 7b and milrinone (M).
Test
Dose (mg/kg) or





MTD and Irwin testb p.o. 300 Number animals (died/treated) 3/3 nt
100 3/3 3/3 (48h)
30 0/3 3/3 (48h)
i.p. 100 3/3 3/3
50 nt 3/3 (24h)
30 0/3 3/3 (48h)
Blood pressure p.o. 30 D% after 1 and 4 h >10% 4/0 nt
10 13/13
5 3/3
Heart rate p.o. 30 D% after 1 and 4 h >20% þ3/þ5 þ7/þ8
CHCl3 arrhythmia i.p. 30 N protected animals/treated 1/3 Lidocaine: 3/3
5 >1/3 0/3 Quinidine (100mg/kg): 3/3
Inotropismc (in vitro) 10 D% >40% þ56 þ72 Trequinsin: þ48
3 þ31 þ60
0.5 þ45















100 Relaxation (%) >50% nt 100










Phenylquinone writhing p.o. 300 Writhing inhibition (%) >50% nt 42 Aspirin (50mg/kg): 68
30 60 nt
10 20 nt
Formalin algesia p.o. 30 Licking time reduction (%) >50% 89 ntd
10 27
nt: not tested.
aWhen not otherwise specified, the drug reference dosage corresponds to that of column 2.
bMTD: maximal tolerated dose; neither significant motor stimulation nor behavioral depression were observed.
cNot blocked by propranolol.
dOnly compounds active in the writhing test were assayed.
594 V. BOIDO ET AL.
to 30 mM (Table 1), while that of compound 7e is characterized by
its steepness, paralleling (at the higher concentrations) that of
digoxin (Figure 2).
Pharmacological screening of compound 7b and milrinone
The most interesting results of the general pharmacological
screening of compounds 7b in comparison with milrinone are
illustrated in Table 3.
First of all, it is observed that the sparteine derivative was mod-
erately toxic, but less than milrinone. Indeed, in both cases at the
dose of 300mg/kg p.o. and 100mg/kg i.p. all treated mice died,
but at lower dose (30mg/kg p.o. and i.p.), no death was observed
with the sparteine derivative within the 72 h of observation,
whereas with milrinone all animals died within 48 h (Table 3). For
comparison, in guinea pig, sparteine sulfate exhibited an i.p. MLD
between 42 and 55mg/kg27, and digoxin exhibited an oral
DL50¼ 3.5mg/kg. In the Irwin test, compound 7b and milrinone
showed neither significant motor stimulation nor behavioral
depression.
Concerning the cardiovascular system, it is observed that the 2-
(4-fluorophenyl)sparteine 7b did not exhibit any activity on the
blood pressure and the heart rate in spontaneously hypertensive
rats, while milrinone showed a moderate reduction of pressure.
Somewhat surprising, 7b did not display significant antiarrhythmic
activity in the chloroform induced arrhythmia assay. In previous
studies16,17, the analogous compounds 6a, 6d, 7a, and 7d, as well
as sparteine, were found to display antifibrillatory activity on iso-
lated frog heart.
More importantly, a net positive inotropic activity was found
for compound 7b and milrinone on isolated, electrically driven
guinea pig left atria. Negative chronotropic action (comparable to
that of quinidine) was observed for the sparteine derivative on
spontaneously beating guinea pig right atria, while milrinone dis-
played positive activity on beating frequency. While the results
reported in Tables 1 and 2 were obtained from reserpinized
guinea pig atria, those reported in Table 3 were from untreated
tissue and the endogenous amines can affect the observed ino-
and chronotropic activities of 7b and milrinone.
The positive inotropism of compound 7b is related neither to
ß-adrenergic receptor activation, since it was not blocked by pro-
pranolol nor to phosphodiesterase inhibition, since the reduction
of tone in guinea pig tracheal strips was not observed, even at
30 mg/mL concentration, while milrinone clearly reduced the tone
of trachea still at 1mg/mL (50%). High positive inotropic activity
on electrically driven guinea pig left atria (from non-reserpinized
animal) was observed19 for a couple of cytisine derivatives (8 and
9; Figure 4). Also in this case, the inotropic activity was not
blocked by propranolol, and no reduction of spontaneous tone of
trachea strips was observed.
Compound 7b exhibited potent saluretic and diuretic activities
(Table 3) that were quite higher than those expressed by furosem-
ide, triamterene, amiloride, and hydroflumethiazide. These activ-
ities were not shared by milrinone.
The combination of diuretic activity with positive inotropism
may result very valuable to relieve symptoms of CHF; therefore,
Figure 3. Chronotropic effects of digoxin, milrinone and compound 7e. p< 0.05
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X= CH2, S
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Figure 5. Some arylalkyl amines with high affinity for sigma-1 receptor.
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the presence of diuretic and saluretic activities should be investi-
gated for the whole set of sparteine derivatives.
Finally, 7b exhibited moderate analgesic (writhing test and for-
malin algesia) and anti-inflammatory (carragenin induced edema)
activities that were not shared by milrinone. The anti-inflammatory
activity seems unrelated to Cox inhibition, since inhibition of ara-
chidonic acid (AA) induced platelet aggregation was not observed;
milrinone completely inhibited the AA induced aggregation even
at 0.1mg/mL concentration.
Thus, the combination of polycyclic alkaloidal frameworks with
particular aromatic moieties, as in compounds 6–9, seems suitable
to generate positive inotropism through a mechanism not related
to adrenergic stimulation or PDE inhibition. The common struc-
tural feature of compounds 6–9 resembles that of some arylalkyl
quinolizidines28 and some arylalkyl amines, like BD-737, BD-1008,
BD-1063, and the butyrophenone antipsychotics (Figure 5) that are
characterized by high affinity to sigma-1 receptor29.
Sigma receptor ligands present well-documented effects on
cardiac muscle30–34, thus the possibility that the inotropic activity
of compounds 6–9 is chaperoned by interaction with sigma recep-
tor is tentatively advanced. This hypothesis is supported by the
excellent fitting of molecules 7b and 7e on the binding site of
sigma 1 receptorial protein (see further). Anyhow, further investi-
gations are needed to define the mechanism of the inotropic
activity of the relevant sparteine derivatives.
Docking studies
Sigma ligands are characterized by a rather large variety of struc-
tures and up to now, the development of potent sigma-1 ligands
was efficiently driven by computational methods, based on hom-
ology studies of the target35 and also fulfilling a pattern of
pharmacophore features exhibited by several series of derivatives,
as discussed in the literature36. Indeed, most of sigma-1 ligands
were characterized by the positive ionizable group and hydrogen
bond acceptor functions connecting at least two hydrophobic
cores. Thus, for sigma-1 ligands, a recurrent binding mode was
proposed in literature, suggesting key contacts with an aspartic
acid residue (D126), as confirmed by mutagenesis experiments37.
More recently, the X-ray crystallographic structure of the
human sigma-1 receptor became available, definitively providing
more reliable avenues to pave the way for the rational design of
further molecules (pdb code¼ 5HK1; resolution¼ 2.51 Å)38.
This computational work was aimed to explore the reliability of
the sigma-1 protein as putative biological target to be proposed
for the newly derivatives here discussed. The main issues to be
addressed were to clarify, through docking studied of the two ser-
ies of compounds 6–7, the role played by the sparteine nucleus
and by the phenyl ring with respect to the co-crystallized ligand
PD144418, bearing a 1-propyl-3-[3-(p-tolyl)isoxazol-5-yl]-1,2,5,6-tet-
rahydropyridine structure (Table 4).
As shown in Figure 6, PD144418 was engaged in salt bridges
involving the protonated nitrogen atom of the tetrahydropyridine
group and D126, E172, giving a good validation of the aforemen-
tioned homology models and mutagenesis data. On the contrary,
the propyl chain and the phenyl ring detected hydrophobic con-
tacts with the surrounding amino acids.
According to our calculations, the most promising compounds
7b and 7e (the R enantiomers proved to be preferred) overlapped
the sparteine nucleus onto the tetrahydropyridine and oxazole
Table 4. Final score (S) derived from MOE docking
calculations













Figure 6. X-ray crystallographic data of the human sigma-1 receptor and of the ligand PD144418. The most important residues are labeled and colored in orange.
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moieties of the reference compound (Figure 7). As a consequence,
the required contacts with D126 and E172 occurred. In addition,
the overall sparteine architecture displayed hydrophobic contacts
with V84, W89, F107, Y120, and F184, as exhibited by the refer-
ence compound oxazole ring and tetrahydropyridine moiety.
Moreover, the phenyl ring of 7b and 7e proved to highly
mimic the role of the one of PD144418, establishing Van der
Waals contacts with L95, A98, L182, and p p stacking with Y103
and Y206. Interestingly, this kind of positioning proved to be
allowed only when small lipophilic substituents decorate the phe-
nyl ring para position, being projected toward a small cavity
delimited by the aforementioned residues L95, A98, and L182.
Indeed, the analogs 7e and 7f were endowed with a better ino-
tropism profile than compound 7d, bearing a less hydrophobic
group.
On the contrary, derivatives characterized by a dehydrospar-
teine nucleus (6b, 6c, 6e, and 6f) differently arranged within the
sigma-1 receptor binding site, due to the more rigid and planar
core. Consequently, they displayed a reversed docking mode with
respect to PD144418, moving the phenyl ring and the dehydro-
sparteine cycle near the phenyl ring and the basic moiety of the
reference compounds.
Concerning sparteine itself, it proved to partially overlap the
related nucleus of the analog 7b, exhibiting a quite comparable
positioning. In particular, it moved much more in proximity of
E172, displaying the required salt-bridge, while any contact with
D126 is lacking. Conceivably, the absence of a phenyl substitution
impairs the possibility to interact with the aforementioned resi-
dues A98, L182, and Y206.
On all these bases, the relevant sparteine derivatives may
indeed act as efficient ligands for sigma-1 receptor.
Conclusions
Ten sparteine derivatives (2-(4-substituted-phenyl)-2-dehydrospar-
teines and 2-(4-substituted-phenyl)sparteines) were tested for ino-
tropic and chronotropic activity on reserpinized guinea pig atria.
Four of them (6b, 6e, 7b, and 7f) exhibited significant inotropic
activity that, at the highest concentrations tested, was followed by
negative inotropism or toxicity. Vice versa, compound 7e (2-(4-tol-
yl)sparteine) exhibited a steep dose-depending positive inotropic
activity up to the highest concentration (300 mM). At 10 mM, its
activity was comparable with that of milrinone, but at 100mM, the
activity of 7e was more than twice that of milrinone. Thus, in com-
parison with digoxin and milrinone, 7e resulted less potent, but
the most active.
The inotropic activity of compound 7b was confirmed on elec-
trically driven left atria from untreated guinea pig and was shown
that its activity was not related to adrenergic stimulation or to
inhibition of phosphodiesterase. A similar behavior was observed
in the past for two, somewhat analogous, arylalkyl derivatives
of cytisine8,9. Therefore, it is advanced the hypothesis that all the
relevant compounds 6–9, characterized by the combination of aro-
matic moieties with polycyclic alkaloidal frameworks, may share
the same mechanism of action. On the base of some structural
similarities between compounds 6–9 and sigma-1 receptor ligands,
endowed with activity on cardiac muscle, it is supposed that the
presently observed inotropic activity might be related to inter-
action with this receptor. Docking studies have, indeed, shown an
excellent fitting of compounds 7b and 7e on the sigma-1 recepto-
rial binding site.
Moreover, compound 7b was shown to possess potent diuretic
and saluretic activities, which might result very valuable in associ-
ation to the positive inotropism to relieve symptoms of CHF.
Figure 7. Docking mode of 7b and of 7e within the X-ray crystallographic data of the human sigma-1 receptor and of the ligand PD144418 (C atom; brown). The
most important residues are labeled.
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Concluding, the 2-arylsparteine pharmacophore appears worthy
of further investigation in order to develop novel agents for the
treatment of CHF.
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